Effects of metabolic parameters' variability on cardiovascular outcomes in diabetic patients.
Blood pressure
Diabetes mellitus
Lipid profile
Metabolic variability
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
15 05 2023
15 05 2023
Historique:
received:
13
03
2023
accepted:
04
05
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Metabolic abnormalities such as dyslipidemia, glucose and high blood pressure are common in diabetic patients. Visit-to-visit variabilities in these measures have been reported as potential residual cardiovascular risk factors. However, the relationship between these variabilities and their effects on cardiovascular prognosis have not been studied. A total of 22,310 diabetic patients with ≥ 3 measurements of systolic blood pressure (SBP), blood glucose, total cholesterol (TC), and triglyceride (TG) levels during a minimum of three years at three tertiary general hospitals were selected. They were divided into high/low variability groups for each variable based on the coefficient of variation (CV) values. The primary outcome was the incidence of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke. All high CV groups had a higher incidence of MACE than those with low CV (6.0% vs. 2.5% for SBP-CV groups, 5.5% vs. 3.0% for TC-CV groups, 4.7% vs. 3.8% for TG-CV groups, 5.8% vs. 2.7% for glucose-CV groups). In multivariable Cox regression analysis,, high SBP-CV (HR 1.79 [95% CI 1.54-2.07], p < 0.01), high TC-CV (HR 1.54 [95% CI 1.34-1.77], p < 0.01), high TG-CV (HR 1.15 [95% CI 1.01-1.31], p = 0.040) and high glucose-CV (HR 1.61 [95% CI 1.40-1.86], p < 0.01) were independent predictors of MACE. Variability of SBP, TC, TG and glucose are important residual risk factors for cardiovascular events in diabetic patients.
Sections du résumé
BACKGROUND
Metabolic abnormalities such as dyslipidemia, glucose and high blood pressure are common in diabetic patients. Visit-to-visit variabilities in these measures have been reported as potential residual cardiovascular risk factors. However, the relationship between these variabilities and their effects on cardiovascular prognosis have not been studied.
METHODS
A total of 22,310 diabetic patients with ≥ 3 measurements of systolic blood pressure (SBP), blood glucose, total cholesterol (TC), and triglyceride (TG) levels during a minimum of three years at three tertiary general hospitals were selected. They were divided into high/low variability groups for each variable based on the coefficient of variation (CV) values. The primary outcome was the incidence of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke.
RESULTS
All high CV groups had a higher incidence of MACE than those with low CV (6.0% vs. 2.5% for SBP-CV groups, 5.5% vs. 3.0% for TC-CV groups, 4.7% vs. 3.8% for TG-CV groups, 5.8% vs. 2.7% for glucose-CV groups). In multivariable Cox regression analysis,, high SBP-CV (HR 1.79 [95% CI 1.54-2.07], p < 0.01), high TC-CV (HR 1.54 [95% CI 1.34-1.77], p < 0.01), high TG-CV (HR 1.15 [95% CI 1.01-1.31], p = 0.040) and high glucose-CV (HR 1.61 [95% CI 1.40-1.86], p < 0.01) were independent predictors of MACE.
CONCLUSION
Variability of SBP, TC, TG and glucose are important residual risk factors for cardiovascular events in diabetic patients.
Identifiants
pubmed: 37189113
doi: 10.1186/s12933-023-01848-x
pii: 10.1186/s12933-023-01848-x
pmc: PMC10186656
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Informations de copyright
© 2023. The Author(s).
Références
Eur J Prev Cardiol. 2017 Jul;24(11):1181-1189
pubmed: 28447480
Cardiovasc Diabetol. 2022 Nov 15;21(1):245
pubmed: 36380325
Cardiovasc Diabetol. 2020 May 2;19(1):50
pubmed: 32359350
Hypertension. 2014 Nov;64(5):965-82
pubmed: 25069669
Am Heart J. 1994 Jun;127(6):1607-14
pubmed: 8197990
J Am Heart Assoc. 2021 Apr 6;10(7):e016947
pubmed: 33728932
J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48
pubmed: 25881936
Cardiovasc Diabetol. 2021 Nov 25;20(1):228
pubmed: 34823536
J Am Heart Assoc. 2023 Mar 7;12(5):e027639
pubmed: 36870945
Fundam Clin Pharmacol. 1999;13(4):501-7
pubmed: 10456293
Diabetes Obes Metab. 2017 Nov;19(11):1570-1578
pubmed: 28432733
Circulation. 2013 Sep 17;128(12):1325-34
pubmed: 23926207
Diabetes Obes Metab. 2020 Oct;22(10):1777-1788
pubmed: 32452623
Eur Heart J. 2017 Oct 01;38(37):2813-2822
pubmed: 28575274
BMJ Open Diabetes Res Care. 2017 Aug 8;5(1):e000427
pubmed: 28878941
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Diabetes Obes Metab. 2019 Dec;21(12):2587-2598
pubmed: 31282073
Lancet. 2010 Mar 13;375(9718):895-905
pubmed: 20226988
Medicine (Baltimore). 2019 Jul;98(29):e16317
pubmed: 31335679
N Engl J Med. 2005 Apr 7;352(14):1425-35
pubmed: 15755765
Am J Cardiol. 2017 Feb 1;119(3):379-387
pubmed: 27939230
Diabetes Metab Syndr Obes. 2020 Jul 01;13:2317-2325
pubmed: 32669865
Eur Heart J. 2017 Dec 21;38(48):3560-3566
pubmed: 29069458
Diabetes Obes Metab. 2018 Apr;20(4):1014-1017
pubmed: 29266630
Atherosclerosis. 2016 Jan;244:86-92
pubmed: 26595903
JAMA. 2015 Feb 10;313(6):603-15
pubmed: 25668264
Circulation. 2018 Dec 4;138(23):2627-2637
pubmed: 30571256
J Am Heart Assoc. 2017 Nov 29;6(12):
pubmed: 29187392
Sci Rep. 2016 Dec 22;6:39633
pubmed: 28004765
J Hum Hypertens. 1994 Jan;8(1):19-22
pubmed: 8151601